Showing 61-70 of 542 results for "".
Evaluating Roflumilast for Seborrheic Dermatitis
https://practicaldermatology.com/series/skin-minute/evaluating-roflumilast-for-seborrheic-dermatitis/54610/Practical Dermatology Editorial Board member Raj Chovatiya, MD, PhD, MSCI, discusses results from the Phase 3 STRATUM trial studying the efficacy of roflumilast for the treatment of seborrheic dermatitis in patients with diverse skin types.Seborrheic Dermatitis Approaches and Stopping Biologic Treatment for Atopic Dermatitis
https://practicaldermatology.com/conferences/scale-2025/seborrheic-dermatitis-approaches-and-stopping-biologic-treatment-for-atopic-dermatitis/35896/Naiem T. Issa, MD, PhD, talks at Music City SCALE 2025 about how to approach seborrheic dermatitis, as well as what happens to atopic dermatitis patients after ending biologic treatments.Improving the After-Sun Treatment Market
https://practicaldermatology.com/series/c-suite-chats/improving-after-sun-treatment-market/29805/Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.The Biggest Developments in Dermatology: Drs. Tsao and Friedlander Provide Updates at Maui Derm
https://practicaldermatology.com/issues/january-february-2025/the-biggest-developments-in-dermatology-drs-tsao-and-friedlander-provide-updates-at-maui-derm/32937/The development of new therapeutics for dermatologic conditions in recent years has been so prolific that Hensin Tsao, MD, PhD, adopted a “Maui Journal of Medicine” theme for his conference-opening presentation at the Maui Derm Hawaii 2025 meeting in Maui, Hawaii.Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyTesting for Persistent Atopic Dermatitis in Pediatric Patients
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37151/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains key considerations when testing for persistent atopic dermatitis in children.Scientifically Speaking: Can We Conquer Cellulite?
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-can-we-conquer-cellulite/19872/Treating cellulite has been a challenge, but new and emerging technologies offer hope to overcome this common condition. Host Joel L. Cohen, MD talks with Nazanin Saedi, MD, Endo's Mike McLane, PhD, and Soliton's Wally Klemp.The Treatment Landscape for Children and Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37153/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, provides an overview of current therapeutic options for pediatric atopic dermatitis patients.“Ask Me Anything” Mentorship Session: Dr. Natasha Mesinkovska on Academia, Alopecia Areata, and More
https://practicaldermatology.com/youngmd-connect/on-demand-virtual-sessions/ask-me-anything-mentorship-session-dr-natasha-mesinkovska-on-academia-alopecia-areata-and-more/48814/Natasha Atanaskova Mesinkovsa, MD, PhD, vice chair for clinical research in the UC Irvine School of Medicine's Department of Dermatology, discusses how she navigated her unique career path, how she balances her various responsibilities now, and more in an "Ask Me Anything" mentorship session.Emerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments i